{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:41:57Z","timestamp":1777329717114,"version":"3.51.4"},"reference-count":46,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10764","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T08:04:18Z","timestamp":1632125058000},"source":"Crossref","is-referenced-by-count":12,"title":["Modern markers for evaluating bone disease in multiple myeloma (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"Vlad","family":"Pop","sequence":"first","affiliation":[{"name":"Hematology Department, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy, 400015 Cluj\u2011Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrada","family":"Parvu","sequence":"additional","affiliation":[{"name":"Hematology Department, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy, 400015 Cluj\u2011Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Craciun","sequence":"additional","affiliation":[{"name":"Medical Biochemistry Department, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy, 400012 Cluj\u2011Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Farcas","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy, 400006 Cluj\u2011Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe","family":"Tomoaia","sequence":"additional","affiliation":[{"name":"Orthopedics and Traumatology Department, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy, 400132 Cluj\u2011Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Bojan","sequence":"additional","affiliation":[{"name":"Hematology Department, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy, 400015 Cluj\u2011Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"issue":"115876","key":"key20211014132744_b1-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115876","article-title":"Bone remineralization of lytic lesions in multiple myeloma-the Arkansas experience","volume":"146","author":"Mohan","year":"2021","journal-title":"Bone"},{"key":"key20211014132744_b2-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.leukres.2012.02.009","article-title":"Could age modify the effect of genetic variants in IL6 and TNF-\u03b1 genes in multiple myeloma?","volume":"36","author":"Martino","year":"2012","journal-title":"Leuk Res"},{"key":"key20211014132744_b3-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1182\/bloodadvances.2020001435","article-title":"Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance","volume":"4","author":"Clay-Gilmour","year":"2020","journal-title":"Blood Adv"},{"issue":"3538","key":"key20211014132744_b4-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103538","article-title":"Hematological diseases and osteoporosis","volume":"21","author":"Gaudio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20211014132744_b5-ETM-0-0-10764","doi-asserted-by":"crossref","first-page":"53","DOI":"10.31768\/2312-8852.2017.39(1):53-56","article-title":"Prognostic value of the bone turnover markers in multiple myeloma","volume":"39","author":"Auzina","year":"2017","journal-title":"Exp Oncol"},{"key":"key20211014132744_b6-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metabolism"},{"key":"key20211014132744_b7-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mc.23272","article-title":"Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma","volume":"60","author":"\u0141acina","year":"2021","journal-title":"Mol Carcinog"},{"key":"key20211014132744_b8-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood.2020006045","article-title":"Monoclonal immunoglobulins promote bone loss in multiple myeloma","volume":"136","author":"Westhrin","year":"2020","journal-title":"Blood"},{"issue":"100425","key":"key20211014132744_b9-ETM-0-0-10764","article-title":"Mechanical unloading enhances bone destruction and tumor expansion in multiple myeloma: Critical roles of osteocytic RANKL induction","volume":"13","author":"Tanimoto","year":"2020","journal-title":"Bone Rep"},{"issue":"100338","key":"key20211014132744_b10-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100338","article-title":"Alkaline phosphatase (ALP) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?","volume":"26","author":"Annibali","year":"2021","journal-title":"J Bone Oncol"},{"key":"key20211014132744_b11-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcdb.2020.10.006","article-title":"Multiple myeloma-a painful disease of the bone marrow","volume":"12","author":"Diaz-delCastillo","year":"2021","journal-title":"Semin Cell Dev Biol"},{"issue":"155358","key":"key20211014132744_b12-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155358","article-title":"Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels","volume":"138","author":"Gu","year":"2021","journal-title":"Cytokine"},{"issue":"2467","key":"key20211014132744_b13-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02467","article-title":"Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy","volume":"9","author":"Toscani","year":"2018","journal-title":"Front Immunol"},{"key":"key20211014132744_b14-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4274\/tjh.2013.0004","article-title":"Bone-specific alkaline phosphatase levels among patients with multiple myeloma receiving various therapy options","volume":"31","author":"\u00c7etin","year":"2014","journal-title":"Turk J Haematol"},{"key":"key20211014132744_b15-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cca.2019.11.012","article-title":"Bone alkaline phosphatase: An important biomarker in chronic kidney disease-mineral and bone disorder","volume":"501","author":"Nizet","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"155271","key":"key20211014132744_b16-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"Jasrotia","year":"2020","journal-title":"Cytokine"},{"key":"key20211014132744_b17-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3324\/haematol.2016.145060","article-title":"Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth","volume":"102","author":"Burger","year":"2017","journal-title":"Haematologica"},{"key":"key20211014132744_b18-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"29820","DOI":"10.18632\/oncotarget.25661","article-title":"Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer","volume":"9","author":"Vainer","year":"2018","journal-title":"Oncotarget"},{"key":"key20211014132744_b19-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lrr.2014.05.002","article-title":"Interaction between IL-6 and TNF-\u03b1 genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT)","volume":"3","author":"Trigo","year":"2014","journal-title":"Leuk Res Rep"},{"key":"key20211014132744_b20-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.intimp.2018.08.016","article-title":"BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6\/JAK2\/STAT3 pathway","volume":"64","author":"Wu","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"key20211014132744_b21-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20211014132744_b22-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lfs.2019.04.060","article-title":"Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes","volume":"228","author":"Ameri","year":"2019","journal-title":"Life Sci"},{"issue":"788","key":"key20211014132744_b23-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"155066","key":"key20211014132744_b24-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155066","article-title":"Importance of TNF-alpha and its alterations in the development of cancers","volume":"130","author":"Mahdavi Sharif","year":"2020","journal-title":"Cytokine"},{"key":"key20211014132744_b25-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.leukres.2013.05.014","article-title":"Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features","volume":"37","author":"Lemancewicz","year":"2013","journal-title":"Leuk Res"},{"issue":"1010","key":"key20211014132744_b26-ETM-0-0-10764","article-title":"Monitoring disease status in multiple myeloma in view of proliferation-leading cytokines","volume":"2","author":"Kovacs-Benke","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"105857","key":"key20211014132744_b27-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2021.105857","article-title":"Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2","volume":"182","author":"Li","year":"2021","journal-title":"Protein Expr Purif"},{"key":"key20211014132744_b28-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/16078454.2018.1552341","article-title":"Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: An updated meta-analysis","volume":"24","author":"Hong","year":"2019","journal-title":"Hematology"},{"issue":"632399","key":"key20211014132744_b29-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs","volume":"12","author":"D'Souza","year":"2021","journal-title":"Front Immunol"},{"issue":"100646","key":"key20211014132744_b30-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100646","article-title":"Why do myeloma patients have bone disease? A historical perspective","volume":"41","author":"B\u00f8rset","year":"2020","journal-title":"Blood Rev"},{"key":"key20211014132744_b31-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/17474086.2019.1640115","article-title":"Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: Can they change the standard of care?","volume":"12","author":"Kleber","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"a031286","key":"key20211014132744_b32-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple myeloma and bone: The fatal interaction","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3924","key":"key20211014132744_b33-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123924","article-title":"Monoclonal antibodies for the treatment of multiple myeloma: An update","volume":"19","author":"Abramson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20211014132744_b34-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv"},{"key":"key20211014132744_b35-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"key20211014132744_b36-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/bs.acc.2017.01.003","article-title":"Measurement and clinical utility of \u03b2CTX in serum and plasma","volume":"81","author":"Chubb","year":"2017","journal-title":"Adv Clin Chem"},{"key":"key20211014132744_b37-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4103\/2230-8210.192914","article-title":"Bone turnover markers: Emerging tool in the management of osteoporosis","volume":"20","author":"Shetty","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"key20211014132744_b38-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.13928","article-title":"Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma","volume":"173","author":"Ting","year":"2016","journal-title":"Br J Haematol"},{"key":"key20211014132744_b39-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","article-title":"Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis","volume":"36","author":"Lorentzon","year":"2019","journal-title":"Adv Ther"},{"key":"key20211014132744_b40-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1080\/10428194.2017.1421757","article-title":"A role for bone turnover markers \u03b2-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma","volume":"59","author":"Vallet","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"68","key":"key20211014132744_b41-ETM-0-0-10764","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-019-1100-6","article-title":"Reference markers of bone turnover for prediction of fracture: A meta-analysis","volume":"14","author":"Tian","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"key20211014132744_b42-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: A report of the international myeloma working group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"key20211014132744_b43-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20211014132744_b44-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/jcrt.JCRT_666_16","article-title":"Serum levels of bone sialoprotein, osteopontin, and \u03b22-microglobulin in stage I of multiple myeloma","volume":"16","author":"Maaroufi","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"key20211014132744_b45-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/s0305-7372(06)80004-6","article-title":"Biochemical markers of bone metabolism in multiple myeloma","volume":"32 (Suppl 1)","author":"Terpos","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"key20211014132744_b46-ETM-0-0-10764","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2013.08.002","article-title":"Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention","volume":"27","author":"Zhou","year":"2013","journal-title":"Blood Rev"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T15:07:50Z","timestamp":1634224070000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,20]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10764","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"article-number":"1329"}}